By Azita Saleki-Gerhardt, Ph.D., executive vice president, operations, AbbVie
While the battle against COVID-19 rages on, it’s important to remember there are millions of patients around the world fighting a variety of chronic and deadly diseases every day, and they rely on medicines and other treatments to live. COVID-19 has created a unique challenge across the supply chain – including unanticipated demand beyond anything seen in years – as we work to make sure those patients get the medicines they need when they need them. For us, the term agility has taken on a new meaning.
Because people around the world depend on our medicines, we’re working hard to prevent any interruption to our production, while protecting the health and safety of our employees. As the head of global Operations at AbbVie and chair of our Executive Crisis Management Team, I have the privilege of working with a fantastic team of leaders across the company to manage the challenges that arise from crises to minimize any impact to employees and our business. Reflecting on past crises, each had a defined scope and duration. In many cases, the incident was limited to one product or geography and we knew with some level of certainty what the endpoint was.